Gazyva

Gazyva (generic name: obinutuzumab) is a targeted cancer treatment used mainly for certain blood cancers like chronic lymphocytic leukemia (CLL) and some forms of lymphoma. It is a type of monoclonal antibody that binds to a protein called CD20 on cancerous B cells, helping the immune system recognize and destroy these abnormal cells. Gazyva is usually given through an IV infusion and may be combined with other treatments. It works by directly attacking cancer cells and engaging the immune system, helping to control the disease and improve patient outcomes.